154 related articles for article (PubMed ID: 1033069)
1. In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages.
Bentley C; Bitter-Suermann D; Hadding U; Brade V
Eur J Immunol; 1976 Jun; 6(6):393-8. PubMed ID: 1033069
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro.
Bentley C; Fries W; Brade V
Immunology; 1978 Dec; 35(6):971-80. PubMed ID: 104925
[TBL] [Abstract][Full Text] [Related]
3. Functional active complement components secreted by guinea pig peritoneal macrophages.
Brade V; Kreuzpaintner G
Immunobiology; 1982 Apr; 161(3-4):315-21. PubMed ID: 7047377
[TBL] [Abstract][Full Text] [Related]
4. Quantitative determination of complement components produced by purified hepatocytes.
Ramadori G; Rasokat H; Burger R; Meyer Zum Büschenfelde KH; Bitter-Suermann D
Clin Exp Immunol; 1984 Jan; 55(1):189-96. PubMed ID: 6692595
[TBL] [Abstract][Full Text] [Related]
5. Effect of cycloheximide and of anti-C3 Fab' on the intrinsic synthesis and secretion of lysosomal enzyme and of complement components by guinea-pig peritoneal macrophages.
Kreuzpaintner G; Brade V
Immunology; 1983 Jun; 49(2):337-42. PubMed ID: 6552217
[TBL] [Abstract][Full Text] [Related]
6. Effect of in vivo stimulation of mice on the secretion of factor B of the alternate complement pathway by peritoneal macrophages.
Bentley C; Hadding U; Bitter-Suermann D; Brade V
Eur J Immunol; 1977 Mar; 7(3):188-90. PubMed ID: 405222
[TBL] [Abstract][Full Text] [Related]
7. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
Hetland G; Bungum L
APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of complement components (C3, C2, B and C1-inhibitor) and lysozyme by human monocytes and macrophages.
Lappin D; Hamilton AD; Morrison L; Aref M; Whaley K
J Clin Lab Immunol; 1986 Jul; 20(3):101-5. PubMed ID: 3638367
[TBL] [Abstract][Full Text] [Related]
9. Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and skynovial membrane cells from patients with rheumatoid arthritis.
de Ceulaer C; Papazoglou S; Whaley K
Immunology; 1980 Sep; 41(1):37-43. PubMed ID: 6903558
[TBL] [Abstract][Full Text] [Related]
10. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific pretranslational regulation of complement production in human mononuclear phagocytes.
Cole FS; Auerbach HS; Goldberger G; Colten HR
J Immunol; 1985 Apr; 134(4):2610-6. PubMed ID: 3844437
[TBL] [Abstract][Full Text] [Related]
12. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
Vogt W; Schmidt G; Dieminger L; Lynen R
Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of gene expression during macrophage activation with a polyribonucleotide. The role of endogenously derived IFN.
Riches DW; Henson PM; Remigio LK; Catterall JF; Strunk RC
J Immunol; 1988 Jul; 141(1):180-8. PubMed ID: 3379303
[TBL] [Abstract][Full Text] [Related]
14. Incompatibility between C3b and B of guinea-pig and man and its influence on the titration of the alternative pathway factors D and B in these two species.
Brade V; Dieminger L; Schmidt G; Vogt W
Immunology; 1976 Feb; 30(2):171-9. PubMed ID: 57093
[TBL] [Abstract][Full Text] [Related]
15. Shedding and synthesis de novo of Fc and C3b receptors by cultured guinea-pig macrophages.
Limb GA; Brown KA; Wolstencroft RA; Dumonde DC
Clin Exp Immunol; 1988 Feb; 71(2):362-7. PubMed ID: 2964964
[TBL] [Abstract][Full Text] [Related]
16. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
17. Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.
Ferluga J; Schorlemmer HU; Baptista LC; Allison AC
Clin Exp Immunol; 1978 Mar; 31(3):512-7. PubMed ID: 657590
[TBL] [Abstract][Full Text] [Related]
18. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
Ruddy S; Austen KF; Goetzl EJ
J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
[TBL] [Abstract][Full Text] [Related]
19. Prevention of immune precipitation by purified components of the alternative pathway.
Naama JK; Holme E; Hamilton E; Whaley K
Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
[TBL] [Abstract][Full Text] [Related]
20. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
